Democratic Defection on Build Back Better Act Sets Back Drive to Lower Drug Prices

U.S. Sen. Joe Manchin’s (D-W.Va.) rejection of his fellow Democrats’ Build Back Better (BBB) policy agenda left its drug pricing section dead in the water.

West Virginia U.S. Sen. Joe Manchin’s rejection Sunday of his fellow Democrats’ Build Back Better (BBB) policy agenda left its drug pricing section dead in the water.

Manchin said of the BBA bill on Dec. 19, “I cannot vote to

Read More »

News Alert: Carole Johnson Will Take Over as HRSA Administrator in January

White House COVID-19 testing czar Carole Johnson will become the next head of the U.S. Health Resources and Services Administration in January.

White House COVID-19 testing czar and long-time Democratic health policy expert Carole Johnson will become the next head of the U.S. Health Resources and Services Administration (HRSA) in January.

HRSA Acting Administrator Diana Espinosa announced Johnson’s selection this afternoon via

Read More »

Breaking News: Lilly Will Honor Unlimited 340B Contract Pharmacy Arrangements in Exchange for Entities’ Claims Data

Drug manufacturer Lilly will let 340B covered entities buy medicines for shipment to an unlimited number of contract pharmacies if entities agree to provide claims-level data associated with such orders.

Drug manufacturer Lilly will let 340B covered entities buy medicines for shipment to an unlimited number of contract pharmacies if entities agree to provide claims-level data associated with such orders, a company spokesperson said late today.

340B hospitals and health

Read More »

U.S. Retail Drug Spending Hit $348.4 Billion in 2020 but Overall Prices Fell 0.1%

New research looked at the prices 340B-enrolled pediatric hospitals charged for pediatric oncology drugs.

U.S. retail prescription drug spending hit $348.4 billion in 2020, constituting 8% of total health care expenditures, a new federal report shows.

The U.S. Centers for Medicare & Medicaid Services (CMS) yesterday published its annual national health care spending report

Read More »

In What Is Believed to Be the First State Action, W.Va. Says Express Scripts’ 340B Claims ID Policy Violates State Law

West Virginia Insurance Commissioner Allan McVey ruled that Express Scripts’ controversial 340B claims identification and submission requirement violates state law.

Pharmaceutical benefit manager Express Scripts’ (ESI) controversial 340B claims identification and submission requirement violates West Virginia law, state Insurance Commissioner Allan McVey has ruled.

McVey on Dec. 8 adopted and approved a hearing examiner’s Nov. 17 finding that ESI’s

Read More »

Senate Finance Committee’s New Drug Pricing Text Includes a New 340B Provision

The U.S. Senate Finance Committee’s latest drug pricing legislation includes 340B language not seen before in earlier House and Senate versions.

The U.S. Senate Finance Committee’s latest drug pricing legislation includes language, not seen before in earlier House and Senate versions, about denying 340B covered entities’ access to government-negotiated lower prices on drugs covered under Medicare.

The committee released the

Read More »

Judge Grants Stay in Boehringer Ingelheim’s 340B Contract Pharmacy Lawsuit

A federal district judge has stayed Boehringer Ingelheim’s 340B contract pharmacy lawsuit.

A federal district judge in Washington, D.C., has paused Boehringer Ingelheim’s (BI) 340B contract pharmacy lawsuit while the federal government decides whether to appeal the same judge’s Nov. 5 joint ruling in Novartis and United Therapeutics’ (UT) contract pharmacy suits.

Read More »

Update: Lilly Comments on Forthcoming New 340B Dispute Resolution Rule

Drug manufacturer Lilly says it hopes the new 340B administrative dispute resolution regulation "addresses the serious shortcomings of the current rule.”

Drug manufacturer Lilly said this morning it looks forward to reviewing the Biden administration’s proposed new 340B administrative dispute resolution (ADR) regulation when it becomes available “and hope[s] that it addresses the serious shortcomings of the current rule.”

“As Lilly

Read More »

News Alert: Biden Administration Plans to Scrap Existing 340B Dispute Resolution Rule and Publish New One Shortly

The Biden administration plans to withdraw its 340B administrative dispute resolution (ADR) regulation and replace it with an entirely new rule.

The Biden administration plans to replace its 340B administrative dispute resolution (ADR) regulation with an entirely new rule that “better aligns with the president’s priorities on drug pricing [and] better reflects the current state of the 340B program.”

The administration

Read More »

Drug Makers May Be Getting Orphan Drug Designations to Exploit 340B Orphan Drug Exclusion, HHS OIG Tells Congress

The 340B orphan drug exclusion may give drug makers a strong incentive to get an orphan designation for their drugs prescribed primarily for common diseases or conditions, a federal watchdog agency reminded Congress this month.

The ban on 340B pricing on orphan drugs for over 1,000 hospitals may give companies that make drugs used primarily for common diseases or conditions a strong financial incentive to get an orphan designation for those drugs, a federal watchdog

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live